Oral Contraception Use and BRCA Penetrance: A Case-Only Study

Patrizia Pasanisi, Guy Hédelin, Jacopo Berrino, Jenny Chang-Claude, Silke Hermann, Michael Steel, Neva Haites, Jacob Hart, Ronit Peled, Lorenzo Gafà, Laura Leggio, Adele Traina, Rosalba Amodio, Maja Primic-Zakelj, Vesna Zadnik, Toomas Veidebaum, Mare Tekkel, Franco Berrino

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

BACKGROUND: Women with deleterious mutations in BRCA genes are at increased risk of breast cancer. However, the penetrance of the genetic trait may be regulated through environmental factors. This multinational case-only study tested the interaction between oral contraceptive use and genetic susceptibility in the occurrence of breast cancer.

METHODS: We recruited 3,123 patients diagnosed with breast cancer before the age of 45 years. Participants were classified according to their probability of carrying a BRCA mutation on the basis of their family history of breast and ovarian cancer. According to a case-only approach, the frequency of relevant exposures among breast cancer cases with high probability of BRCA mutation ("genetic cases") was compared with the frequency of the same exposures among breast cancer cases with a low probability of BRCA mutation ("sporadic cases"). The interaction odds ratios (OR) and 95% confidence intervals (CI) for oral contraceptive use were estimated by unconditional logistic regression, after controlling for potentially confounding variables.

RESULTS: The analysis was carried out comparing 382 "genetic" and 1,333 "sporadic" cases. We found a borderline significant interaction between genetic breast cancer and oral contraceptive use for ever users compared with never users (OR, 1.3; 95% CI, 1.0-1.7). The greatest interaction OR was found for women who started using pill at 18 to 20 years (OR, 1.6; 95% CI, 1.1-2.3).

CONCLUSION: These results suggest that BRCA mutation carriers, as well as women with a significant family history of breast and ovarian cancer are more vulnerable to exogenous hormones in oral contraceptives.
Original languageEnglish
Pages (from-to)2107-2113
Number of pages7
JournalCancer Epidemiology, Biomarkers and Prevention
Volume18
Issue number7
Early online date23 Jun 2009
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Penetrance
Contraception
Breast Neoplasms
Oral Contraceptives
Mutation
Odds Ratio
Confidence Intervals
Ovarian Neoplasms
Confounding Factors (Epidemiology)
Mouth Neoplasms
Genetic Predisposition to Disease
Logistic Models
Hormones

Keywords

  • adolescent
  • adult
  • age of onset
  • BRCA2 protein
  • breast neoplasms
  • case-control studies
  • contraceptives, oral
  • Europe
  • female
  • genes, BRCA1
  • genetic predisposition to disease
  • humans
  • logistic models
  • models, genetic
  • pedigree
  • penetrance
  • questionnaires
  • risk assessment
  • risk factors
  • time factors
  • young adult

Cite this

Pasanisi, P., Hédelin, G., Berrino, J., Chang-Claude, J., Hermann, S., Steel, M., ... Berrino, F. (2009). Oral Contraception Use and BRCA Penetrance: A Case-Only Study. Cancer Epidemiology, Biomarkers and Prevention, 18(7), 2107-2113. https://doi.org/10.1158/1055-9965.EPI-09-0024

Oral Contraception Use and BRCA Penetrance : A Case-Only Study. / Pasanisi, Patrizia; Hédelin, Guy; Berrino, Jacopo; Chang-Claude, Jenny; Hermann, Silke; Steel, Michael; Haites, Neva; Hart, Jacob; Peled, Ronit; Gafà, Lorenzo; Leggio, Laura; Traina, Adele; Amodio, Rosalba; Primic-Zakelj, Maja; Zadnik, Vesna; Veidebaum, Toomas; Tekkel, Mare; Berrino, Franco.

In: Cancer Epidemiology, Biomarkers and Prevention, Vol. 18, No. 7, 07.2009, p. 2107-2113.

Research output: Contribution to journalArticle

Pasanisi, P, Hédelin, G, Berrino, J, Chang-Claude, J, Hermann, S, Steel, M, Haites, N, Hart, J, Peled, R, Gafà, L, Leggio, L, Traina, A, Amodio, R, Primic-Zakelj, M, Zadnik, V, Veidebaum, T, Tekkel, M & Berrino, F 2009, 'Oral Contraception Use and BRCA Penetrance: A Case-Only Study' Cancer Epidemiology, Biomarkers and Prevention, vol. 18, no. 7, pp. 2107-2113. https://doi.org/10.1158/1055-9965.EPI-09-0024
Pasanisi P, Hédelin G, Berrino J, Chang-Claude J, Hermann S, Steel M et al. Oral Contraception Use and BRCA Penetrance: A Case-Only Study. Cancer Epidemiology, Biomarkers and Prevention. 2009 Jul;18(7):2107-2113. https://doi.org/10.1158/1055-9965.EPI-09-0024
Pasanisi, Patrizia ; Hédelin, Guy ; Berrino, Jacopo ; Chang-Claude, Jenny ; Hermann, Silke ; Steel, Michael ; Haites, Neva ; Hart, Jacob ; Peled, Ronit ; Gafà, Lorenzo ; Leggio, Laura ; Traina, Adele ; Amodio, Rosalba ; Primic-Zakelj, Maja ; Zadnik, Vesna ; Veidebaum, Toomas ; Tekkel, Mare ; Berrino, Franco. / Oral Contraception Use and BRCA Penetrance : A Case-Only Study. In: Cancer Epidemiology, Biomarkers and Prevention. 2009 ; Vol. 18, No. 7. pp. 2107-2113.
@article{885bfb8c45ef40a3adbd3b13f474eca9,
title = "Oral Contraception Use and BRCA Penetrance: A Case-Only Study",
abstract = "BACKGROUND: Women with deleterious mutations in BRCA genes are at increased risk of breast cancer. However, the penetrance of the genetic trait may be regulated through environmental factors. This multinational case-only study tested the interaction between oral contraceptive use and genetic susceptibility in the occurrence of breast cancer.METHODS: We recruited 3,123 patients diagnosed with breast cancer before the age of 45 years. Participants were classified according to their probability of carrying a BRCA mutation on the basis of their family history of breast and ovarian cancer. According to a case-only approach, the frequency of relevant exposures among breast cancer cases with high probability of BRCA mutation ({"}genetic cases{"}) was compared with the frequency of the same exposures among breast cancer cases with a low probability of BRCA mutation ({"}sporadic cases{"}). The interaction odds ratios (OR) and 95{\%} confidence intervals (CI) for oral contraceptive use were estimated by unconditional logistic regression, after controlling for potentially confounding variables.RESULTS: The analysis was carried out comparing 382 {"}genetic{"} and 1,333 {"}sporadic{"} cases. We found a borderline significant interaction between genetic breast cancer and oral contraceptive use for ever users compared with never users (OR, 1.3; 95{\%} CI, 1.0-1.7). The greatest interaction OR was found for women who started using pill at 18 to 20 years (OR, 1.6; 95{\%} CI, 1.1-2.3).CONCLUSION: These results suggest that BRCA mutation carriers, as well as women with a significant family history of breast and ovarian cancer are more vulnerable to exogenous hormones in oral contraceptives.",
keywords = "adolescent, adult, age of onset, BRCA2 protein, breast neoplasms, case-control studies, contraceptives, oral, Europe, female, genes, BRCA1, genetic predisposition to disease, humans, logistic models, models, genetic, pedigree, penetrance, questionnaires, risk assessment, risk factors, time factors, young adult",
author = "Patrizia Pasanisi and Guy H{\'e}delin and Jacopo Berrino and Jenny Chang-Claude and Silke Hermann and Michael Steel and Neva Haites and Jacob Hart and Ronit Peled and Lorenzo Gaf{\`a} and Laura Leggio and Adele Traina and Rosalba Amodio and Maja Primic-Zakelj and Vesna Zadnik and Toomas Veidebaum and Mare Tekkel and Franco Berrino",
year = "2009",
month = "7",
doi = "10.1158/1055-9965.EPI-09-0024",
language = "English",
volume = "18",
pages = "2107--2113",
journal = "Cancer Epidemiology, Biomarkers and Prevention",
issn = "1055-9965",
publisher = "AMER ASSOC CANCER RESEARCH",
number = "7",

}

TY - JOUR

T1 - Oral Contraception Use and BRCA Penetrance

T2 - A Case-Only Study

AU - Pasanisi, Patrizia

AU - Hédelin, Guy

AU - Berrino, Jacopo

AU - Chang-Claude, Jenny

AU - Hermann, Silke

AU - Steel, Michael

AU - Haites, Neva

AU - Hart, Jacob

AU - Peled, Ronit

AU - Gafà, Lorenzo

AU - Leggio, Laura

AU - Traina, Adele

AU - Amodio, Rosalba

AU - Primic-Zakelj, Maja

AU - Zadnik, Vesna

AU - Veidebaum, Toomas

AU - Tekkel, Mare

AU - Berrino, Franco

PY - 2009/7

Y1 - 2009/7

N2 - BACKGROUND: Women with deleterious mutations in BRCA genes are at increased risk of breast cancer. However, the penetrance of the genetic trait may be regulated through environmental factors. This multinational case-only study tested the interaction between oral contraceptive use and genetic susceptibility in the occurrence of breast cancer.METHODS: We recruited 3,123 patients diagnosed with breast cancer before the age of 45 years. Participants were classified according to their probability of carrying a BRCA mutation on the basis of their family history of breast and ovarian cancer. According to a case-only approach, the frequency of relevant exposures among breast cancer cases with high probability of BRCA mutation ("genetic cases") was compared with the frequency of the same exposures among breast cancer cases with a low probability of BRCA mutation ("sporadic cases"). The interaction odds ratios (OR) and 95% confidence intervals (CI) for oral contraceptive use were estimated by unconditional logistic regression, after controlling for potentially confounding variables.RESULTS: The analysis was carried out comparing 382 "genetic" and 1,333 "sporadic" cases. We found a borderline significant interaction between genetic breast cancer and oral contraceptive use for ever users compared with never users (OR, 1.3; 95% CI, 1.0-1.7). The greatest interaction OR was found for women who started using pill at 18 to 20 years (OR, 1.6; 95% CI, 1.1-2.3).CONCLUSION: These results suggest that BRCA mutation carriers, as well as women with a significant family history of breast and ovarian cancer are more vulnerable to exogenous hormones in oral contraceptives.

AB - BACKGROUND: Women with deleterious mutations in BRCA genes are at increased risk of breast cancer. However, the penetrance of the genetic trait may be regulated through environmental factors. This multinational case-only study tested the interaction between oral contraceptive use and genetic susceptibility in the occurrence of breast cancer.METHODS: We recruited 3,123 patients diagnosed with breast cancer before the age of 45 years. Participants were classified according to their probability of carrying a BRCA mutation on the basis of their family history of breast and ovarian cancer. According to a case-only approach, the frequency of relevant exposures among breast cancer cases with high probability of BRCA mutation ("genetic cases") was compared with the frequency of the same exposures among breast cancer cases with a low probability of BRCA mutation ("sporadic cases"). The interaction odds ratios (OR) and 95% confidence intervals (CI) for oral contraceptive use were estimated by unconditional logistic regression, after controlling for potentially confounding variables.RESULTS: The analysis was carried out comparing 382 "genetic" and 1,333 "sporadic" cases. We found a borderline significant interaction between genetic breast cancer and oral contraceptive use for ever users compared with never users (OR, 1.3; 95% CI, 1.0-1.7). The greatest interaction OR was found for women who started using pill at 18 to 20 years (OR, 1.6; 95% CI, 1.1-2.3).CONCLUSION: These results suggest that BRCA mutation carriers, as well as women with a significant family history of breast and ovarian cancer are more vulnerable to exogenous hormones in oral contraceptives.

KW - adolescent

KW - adult

KW - age of onset

KW - BRCA2 protein

KW - breast neoplasms

KW - case-control studies

KW - contraceptives, oral

KW - Europe

KW - female

KW - genes, BRCA1

KW - genetic predisposition to disease

KW - humans

KW - logistic models

KW - models, genetic

KW - pedigree

KW - penetrance

KW - questionnaires

KW - risk assessment

KW - risk factors

KW - time factors

KW - young adult

U2 - 10.1158/1055-9965.EPI-09-0024

DO - 10.1158/1055-9965.EPI-09-0024

M3 - Article

VL - 18

SP - 2107

EP - 2113

JO - Cancer Epidemiology, Biomarkers and Prevention

JF - Cancer Epidemiology, Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -